baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Galapagos N.V./ BE0003818359 /

2024-04-24 7:57:24 AM	Chg. +0.3800	Volume	Bid4:25:58 PM	Ask4:25:58 PM	Market Capitalization	Dividend Y.	P/E Ratio
27.5200EUR	+1.40%	- Turnover: -	27.1600Bid Size: 188	27.2000Ask Size: 188	1.79 bill.EUR	-	8.49

GlobeNewswire 04-04 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...

GlobeNewswire 03-28 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

GlobeNewswire 03-26 Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

GlobeNewswire 02-22 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Cl...

GlobeNewswire 02-22 Galapagos announces full year 2023 results and outlook for 2024

GlobeNewswire 02-15 Galapagos presents at EBMT-EHA annual meeting 2024

GlobeNewswire 02-05 NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

GlobeNewswire 01-31 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma

GlobeNewswire 01-04 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...

GlobeNewswire 01-03 Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule dru...

GlobeNewswire 01-02 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

GlobeNewswire 2023-12-22 Oceana Finds China’s Fishing Fleet Swarms Galápagos, then Disappears from Sight

GlobeNewswire 2023-12-19 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...

GlobeNewswire 2023-12-09 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...

GlobeNewswire 2023-12-07 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...

GlobeNewswire 2023-11-02 Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies fo...

GlobeNewswire 2023-11-01 SweetWater Brewing Company Launches Special-Edition 420 IPA in Partnership With the Georgia Aquarium...

GlobeNewswire 2023-10-30 Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business t...

GlobeNewswire 2023-09-19 Galapagos appoints Simon Sturge to its Board of Directors

GlobeNewswire 2023-08-28 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with...

GlobeNewswire 2022-03-28 Jyseleca® approved in Japan for ulcerative colitis

GlobeNewswire 2022-03-24 Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholde...

GlobeNewswire 2022-03-24 Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings

GlobeNewswire 2022-03-18 Galapagos increases share capital through subscription right exercises

GlobeNewswire 2022-02-24 Galapagos 2021 results set stage for future growth

Galapagos N.V./ BE0003818359 /

If you wish to receive reply to your feedback, please provide your email address.